Page 18 - Teddy Whiley News Today

Investegate announcements from Omega Diagnostics Gp, UK Government contract and trading update

    Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces the appointment of Dr Simon Douglas as independent Non-Executive Chairman. Simon has been appointed to the Board with immediate effect, after a thorough search process that was conducted with the help of Snedden Campbell Ltd. Simon has also become a member of both the Audit Committee and the Remuneration Committee.   Simon has 25 year...

ANGLE plc: Angle Plc - Announces Parsortix: Dynamic Assessment of Patient Response Use of Parsortix System Enables a Dynamic Assessment of Patient Response to Treatment in Non-Small Cell Lung Cancer CTCs harvested by the Parsortix system successfully used to measure the dynamic role of EMT and PD-L1 in patient response to therapy Findings support ANGLEs plan for the growth of a new "pharma services" business area using the Parsortix system as a biomarker for cancer drug trials allowing longitu...

CANCER-ID was a European consortium funded by the Innovative Medicines Initiative (IMI) aimed at the establishment of standard protocols for and clinical validation of blood-based biomarkers. It brought together experts from academic and clinical research, innovative Small-to-Medium sized Enterprises (SMEs), diagnostics companies and the pharmaceutical industry thus providing a unique setting for establishing clinical utility of "liquid biopsies".   About ANGLE plc ...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

ANGLE plc: Angle PLC - Parsortix Demonstrates High Capture Rate of CTCs Parsortix system demonstrates high capture rate of CTCs irrespective of biomarker status or phenotype GUILDFORD, SURREY / ACCESSWIRE / January 29, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the publication of a five year programme of work undertaken by the CANCER-ID Consortium to establish the performance and technical capabilities of five circulating tumour cell (...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

  Xeros Technology Group plc develops and licenses platform technologies which transform the sustainability, performance and economics of water intensive industrial and commercial processes. Xeros patented XOrb™  technologies significantly reduce the amount of water used in the dyeing, finishing or laundering of soft substrates such as garments and fabrics. They enable the remaining water to become far more efficient and effective in either affixing or removing mole...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...